HISTORY

Dextro-Sang Corporation was founded in 1999 by Dr. Jan Blumenstein and Dr. Jeffrey Wong, the scientists who initially developed Dextran-Hemoglobin a transfusable product that is designed to deliver oxygen to vital organs during times of patient crises resulting from severe blood losses.

Dextran-Hemoglobin was first developed and tested at the University of Toronto and Mount Sinai (Toronto) Hospital in the late 1970’s. Since then, several rigorous tests have been performed successfully on a variety of animal species (dogs, cats, swine, guinea pigs and monkeys) to examine the safety and efficacy of Dextran-Hemoglobin. As well, testing has been conducted to assess industrial production efficiency, virus removal methods and its economic viability as a transfusable alternative to blood.

DSC believes that a viable blood substitute must meet the following criteria:

• Improve patient safety in a variety of conditions by delivering oxygen to vital organs as needed.
• Offer unqualified safety from viral contamination.
• Offer ease of handling: A long shelf life. Universality for all patients regardless of blood type.
• Offer the opportunity for a broad range field uses such as at accident scenes, in ambulances, on battlefields, in disaster situations such as the recent Tsunami in Thailand.
• Address emergencies of shortages in hospitals and regions where the World Health Organization has identified severe supply deficiencies.
• A manufacturing process that is efficient, economical and deliverable to those regions in need.

TODAY

In the fall of 2004, DSC was invited by a clinical group in Thailand to consider undertaking trials of Dextran-Hemoglobin in Bangkok. Thailand is one of Asia’s leaders in the field of Health Care, with an annual income of one billion dollars (USD) from foreign patients who travel to Thailand specifically for medical treatment. To support this growing Health Care sector, the Thai government has announced several funding programs to attract international biotechnology projects. Moreover, it has adopted a flexible regulatory strategy (based on the Australian model) that is designed to reduce the costs and time frames of the regulatory process. Based on input from DSC’s independent consultant and its Thai partner, DSC formed the opinion that Thai regulatory approval of Dextran-Hemoglobin can be achieved in less than two years.

As a result of this environment, several biotechnology companies from Europe and North America have begun scientific initiatives in Bangkok. In addition, the World Health Organization has determined that there are severe shortages in blood supplies in South East Asia because of donor infection and inadequate blood collecting programs. For these reasons, DSC adopted Thailand as its first jurisdiction to obtain regulatory approval of Dextran-Hemoglobin and since October 2004, has developed a growing network of government agencies, hospitals, clinicians, pharmaceutical companies and universities to assist in the project.

HONG KONG UNIVERSITY OF SCIENCE & TECHNOLOGY

DSC has signed a research and development contract with Hong Kong University of Science and Technology. Under that agreement, Dr. Wong and his staff are conducting further research and producing product for animal testing.

STRATEGIC PARTNERSHIPS

Currently, DSC is negotiating strategic partnerships with several biotechnology companies that will meet needs of production, marketing and distribution in South-East Asia, the Middle East and Africa.